Breyer, E. (2008): Reimbursement processes – An analysis of international practice models for maintaining the health benefit baskets of solidly financed health care systems. HTA-Projektbericht 022.

Buzath, K. and Zechmeister-Koss, I. (2023): Economic Dimensions of Community Nursing: A Systematic Literature Review. HTA-Projektbericht 153.

Böhler, C.E.H. and Wolf, S. (2020): Lung Cancer Screening in Risk Groups: A Review-Update of the Economic Evidence (Part II). HTA-Projektbericht 132b.

Fischer, S. and Novelli, A. (2016): Re-orientation of the Austrian parent-child preventive care programme. Part XII: Economic evaluation of selected screenings during pregnancy. HTA-Projektbericht 91.

Fischer, S. and Stanak, M. (2017): Social Return on Investment: Outcomes, Methods, and Economic Parameters. HTA-Projektbericht 96.

Fischer, S. and Tüchler, H. and Piso, B. (2016): Outpatient cardiac rehabilitation part VII: Economic Evaluation. HTA-Projektbericht 89.

Fischer, S. and Zechmeister-Koss, I. (2014): Costs of day surgery in Austria: An analysis of data and methods for varicose vein surgery as an example. HTA-Projektbericht 71.

Fried, A. and Wild, C. (2016): Involvement of Citizens and Patients in HTA-Processes – International Experiences and Good Practice Examples. HTA-Projektbericht 86.

Fried, A. and Wild, C. (2013): Hybrid operating room. Rapid Assessment 006.

Gregor-Patera, N. (2023): Sponsoring of patient initiatives in Austria. 5th Update of the Systematic Analyses 2014 to 2019. AIHTA Policy Brief 007/ 5. Update.

Gregor-Patera, N. and Petersen, P. and Wild, C. (2017): Sponsoring of Patient Initiatives in Austria 2016. Update of the Systematic Analyses 2015 and 2014. Rapid Assessment 007b_2. Update 2017.

Gregor-Patera, N. and Schader , M. and Wild, C. (2016): Non-interventional studies (NIS) in Austria. A systematic analysis. Rapid Assessment 007c.

Gregor-Patera, N. and Wild, C. (2017): Research interests of Non-interventional studies (NIS) in Austria. Update of the systematic analysis. Rapid Rapid Assessment 007c. Update 2017.

Grössmann, N. and Wild, C. and Mayer, J. (2016): Drugs in Oncology: an overview of benefit and refund practices in Europe. Rapid Assessment 008.

Hawlik, K. and Stanak, M. (2017): Perinatal care at the threshold of viability; Part I: Systematic Analysis of Outcomes and Resource Needs for Neonatal Intensive Care Units to inform Healthcare Planning. HTA-Projektbericht 97a.

Knapp, M. and Mc Daid, D. and Amaddeo, F. and Zechmeister, I. (2007): Financing Mental Health Care in Europe. Journal of Mental Health 16 (02): pp. 167-180.

Korencan, A. (2007): [Diagnosis of cytomegalovirus disease in immunocompromised patients]. HTA-Newsletter 53: p. 4.

Mantsch, S. and Petersen, P. and Wild, C. (2016): Pharma: Disclosure of payments in Austria 2015. Rapid Assessment 007d.

Nachtnebel, A. (2009): [Coverage with Evidence Development - Experiences from selected countries]. HTA-Projektbericht 024.

Patera, N. (2011): Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research. HTA-Projektbericht 48.

Patera, N. and Schumacher, I. (2012): Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition). HTA-Projektbericht 41b.

Petersen, P. and Wild, C. (2017): Sponsoring of Patientinitiatives in Austria 2015. Update of the Systematic Analysis 2014.. Rapid Assessment 007b_1. Update 2017.

Radlberger, P. and Zechmeister, I. (2010): Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs. HTA-Projektbericht 41b.

Schmidt, L. and Prenner, A. and Lohr, P. and Wild, C. (2019): Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies. HTA-Projektbericht 120.

Sehic, O. (2021): Sponsoring of patient initiatives in Austria. Update of the Systematic Analyses 2014 to 2018. AIHTA Policy Brief 007.

Sehic, O. and Wild, C. (2021): Non-interventional studies (NIS) in Austria, 2nd update of systematic analyses 2016 & 2017. AIHTA Policy Brief 010.

Sehic, O. (2019): Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015. Rapid Assessment 007d_1. Update 2019.

Siebert, U. (2006): [Decision-analytic modelling: Aims, strengths and limitations. Editorial]. HTA-Newsletter 45: pp. 1-2.

Stanak, M. and Strohmaier, C. (2019): Minimum volume standards for quality assurance in day surgery: Fundamentals and Systematic Review. HTA-Projektbericht 125.

Strohmaier, C. and Hölzle, L. (2021): The economic and societal dimension of parental mental illness. HTA-Projektbericht 142.

Strohmaier, C. and Zechmeister-Koss, I. (2024): Threshold values in health economic evaluations and decision-making. HTA-Projektbericht 163.

Tsvenhrosh, A. and Sehic, O. (2019): Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016. Rapid Assessment 007b_3. Update 2019.

Velasco-Garrido, M. and Busse, R. (2007): [Health baskets in 9 countries of the EU. Editorial]. HTA-Newsletter 56: p. 1.

Walter, M. and Strohmaier, C. (2020): Genetic Testing in the Context of Familial Hypercholesterolaemia Management. HTA-Projektbericht 130.

Wild, C. and Fabian, D. (2024): The Role of Public Contributions to the Development of Health Innovations. HTA-Projektbericht 158.

Wild, C. (2006): [Antiviral treatment for chronic hepatitis C]. HTA-Newsletter 45: p. 4.

Wild, C. (2006): [Infliximab for Crohn’s disease]. HTA-Newsletter 45: p. 2.

Wild, C. (2006): [Interferon-beta for multiple sklerosis]. HTA-Newsletter 45: pp. 2-3.

Wild, C. (2004): [Drug eluting stents: An economic analysis]. HTA-Newsletter 31: pp. 3-4.

Wild, C. (2004): [Prevention and therapy of Hepatitis C]. HTA-Newsletter 29: pp. 3-4.

Wild, C. (2003): [Cardiac resynchronisation therapy (CRT) for heart failure]. HTA-Newsletter 23: pp. 3-4.

Wild, C. (2003): [Recombinant human growth hormone (GH) therapy]. HTA-Newsletter 21: p. 2.

Wild, C. (2003): [Ambulatory versus stationary haemodialysis for people with end-stage renal failure]. HTA-Newsletter 20: p. 4.

Wild, C. (2003): [Clinical economics]. ITA-Newsletter September 2003: pp. 10-11.

Wild, C. (2003): [Clinical economics. Editorial]. HTA-Newsletter 19: pp. 1-2.

Wild, C. (2003): [Use of genotypic resistance testing to optimise HIV-therapy]. HTA-Newsletter 14: p. 3.

Wild, C. (2002): [Infliximab for Crohn's disease]. HTA-Newsletter 11: p. 4.

Wild, C. (2002): [Drug therapy for adiposity]. HTA-Newsletter 08: pp. 3-4.

Wild, C. (2002): [COX-2 inhibitors in the treament of arthritis]. HTA-Newsletter 06: p. 4.

Wild, C. and Zechmeister, I. (2007): [Allocation of resources and equity. Editorial]. HTA-Newsletter 59: p. 1.

Wild, C. (2012): Avastin for Age-related Macular-Degeneration. Evidence synthesis after CATT, IVAN, MANTA. Rapid Assessment 005.

Wild, C. (2005): Ethics of Resource Allocation: Instruments for rational decision-making in support of a sustainable health care. Poiesis & Praxis: International Journal of Ethics of Science and Technology Assessment 03 (04): pp. 296-309.

Wild, C. (2005): [Health technology assessment, economics and health]. Austrian Public Health association conference. Linz, 07.-08.06.2005.

Wild, C. and Khan, A. and Erdos, J. (2015): Sponsoring of Patient Initiatives in Austria. Systematic Analysis. Rapid Assessment 007b.

Wild, C. and Zechmeister, I. (2007): [Theories of distributional justice in health care and the role of HTA]. Kurswechsel 2: pp. 87-88.

Wohlhöfner, K. (2021): (Good) practice organisational models using real-world evidence for public funding of high prized therapies. HTA-Projektbericht 138.

Wolf, S. and Fischer, S. (2017): Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations. HTA-Projektbericht 95a.

Wolf, S. and Wild, C. (2018): Drug reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process, taking into account international experience . HTA-Projektbericht 109.

Zechmeister, I. (2008): [Vaccination against HPV in Austria]. HTA-Newsletter 64: p. 2.

Zechmeister, I. (2007): [Treatment of mental disorders. Editorial]. HTA-Newsletter 60: p. 1.

Zechmeister, I. (2007): [Hepatitis C therapy]. HTA-Newsletter 59: p. 2.

Zechmeister, I. (2006): [HPV immunisation: Different strategies]. HTA-Newsletter 50: pp. 3-4.

Zechmeister, I. (2006): [Statins: Economic evaluation]. HTA-Newsletter 48: p. 2.

Zechmeister, I. and Freiesleben de Blasio, B. and Radlberger, P. and Wild, C. and Kvas, E. and Garnett, G. and Neilson, A. R. (2007): [Economic evaluation of HPV vaccination in Austria]. HTA-Projektbericht 09.

Zechmeister, I. and Sroczynski, G. and Rafetseder, O. and Jonas, S. (2006): [Chronic hepatitis C: Decision analytic modeling]. ITA-Projektbericht 29.

Zechmeister, I. and Wild, C. (2006): [Statins and their prognosed as well as real impact on hospital services in Austria]. ITA-Projektbericht 30.

Zechmeister, I. (2008): [Modelling-based economic evaluation in the context of Health Technology Assessment: Examples from Austria]. Workshop of the Austrian Society for Operational Research. Vienna, 23.02.2008.

Zechmeister, I. (2008): [Economic evaluation of the vaccination against human papillomavirus in Austria]. Is prevention always better than cure?. Krems, 20.-21.02.2008.

Zechmeister, I. (2008): [HPV-vaccination in Austria. A prediction on long-term effects and costs]. Biomed Austria (Frühling 2008): pp. 8-9.

Zechmeister, I. (2007): [Is it worth investing in mental health promotion and prevention of mental disorders? Evidence from economic evaluations]. In: Meggeneder, O. Tagungsband zur Wissenschaftlichen Jahrestagung der Österreichischen Gesellschaft für Public Health: Linz: Österreichische Gesellschaft für Public Health. (In Press)

Zechmeister, I. (2006): [Is it worth investing in mental health promotion and prevention of mental illness? A review of the evidence on economic evaluations]. 9th conference of the Austrian Public Health Association. Linz, 28.-29.09.2006.

Zechmeister, I. (2006): [Current guidelines for health economic evaluation. Austria in comparison with Canada. Editorial]. HTA-Newsletter 48: p. 1.

Zechmeister, I. (2006): [Cost-effectiveness of statins]. ITA-Newsletter March 2006: p. 3.

Zechmeister, I. (2006): [Women, think economically?! Ambivalences of current economic thinking. The case of health economics]. Beiträge zur Feministischen Theorie und Praxis 68: pp. 115-127.

Zechmeister, I. (2005): [Financing health care: Challenges for psychiatry]. ITA-Newsletter December 2005: pp. 4-5.

Zechmeister, I. and Kilian, R. and Mc Daid, D. (2008): Is it worth investing in mental health promotion and prevention of mental illness? A systematic review of the evidence from economic evaluations. BMC Public Health 08 (20).

Zechmeister, I. and Loibl, T. (2011): Reorientation of the Austrian parent-child preventive care programme. Part III: Financing structures of services and public transfers for parents and young children. HTA-Projektbericht 045c.

Zechmeister, I. and Radlberger, P. (2007): [Health economic evaluation]. WMW: Wiener Medizinische Wochenschrift 2007. (Submitted)

Zechmeister, I. and Österle, A. (2007): [Informal care of people with mental disorders: Does the Austrian long-term care system provide adequate support?]. Neuropsychiatrie 21 (1): pp. 29-36.

Zechmeister, I. and Österle, A. (2006): Distributional impacts of mental health care financing arrangements: A comparison of the UK, Germany and Austria. Journal of Mental Health Policy and Economics 9 (1): pp. 34-44.

Zechmeister-Koss, I. and Fischer, S. and Erdos, J. (2012): Re-orientation of the Austrian parent-child preventive care programme. Part VIII: Review of economic evaluations and budget impact analysis of outreach services and measures to reduce premature birth. HTA-Projektbericht 55.